Therapeutics Company Announces Dissemination of Positive Results From Rhinitis Trial

Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company focused on developing and commercializing RNA delivery technology for targets beyond the liver, recently announced the dissemination of positive results from its NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR). These results were shared via video formats on the social media channels of Allergy, one of the highest-ranking journals in the field of allergology worldwide. This announcement follows the journal's April publication of the peer-reviewed article titled "AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial," which detailed the pivotal trial's findings. $Altamira Therapeutics(CYTO.US)$